243 related articles for article (PubMed ID: 33054579)
21. Characterization of a five-microRNA signature as a prognostic biomarker for esophageal squamous cell carcinoma.
Yu J; Zhu M; Lv M; Wu X; Zhang X; Zhang Y; Li J; Zhang Q
Sci Rep; 2019 Dec; 9(1):19847. PubMed ID: 31882677
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.
Kang YY; Li JJ; Sun JX; Wei JX; Ding C; Shi CL; Wu G; Li K; Ma YF; Sun Y; Qiao H
Clin Transl Oncol; 2021 Dec; 23(12):2536-2547. PubMed ID: 34245428
[TBL] [Abstract][Full Text] [Related]
23. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
[TBL] [Abstract][Full Text] [Related]
24. Study on miRNAs in Pan-Cancer of the Digestive Tract Based on the Illumina HiSeq System Data Sequencing.
Lai CH; Liang XZ; Liang XY; Ma SJ; Li JG; Shi MF; Zhu X; Lan HH; Zeng JH
Biomed Res Int; 2019; 2019():8016120. PubMed ID: 31737678
[TBL] [Abstract][Full Text] [Related]
25. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
26. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
Chen F; Li Z; Deng C; Yan H
J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
[TBL] [Abstract][Full Text] [Related]
27. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.
Geraldo MV; Nakaya HI; Kimura ET
Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816
[TBL] [Abstract][Full Text] [Related]
30. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.
Han ZB; Zhong L; Teng MJ; Fan JW; Tang HM; Wu JY; Chen HY; Wang ZW; Qiu GQ; Peng ZH
Mol Oncol; 2012 Aug; 6(4):445-57. PubMed ID: 22552153
[TBL] [Abstract][Full Text] [Related]
31. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
[TBL] [Abstract][Full Text] [Related]
32. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
33. hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B.
Lu H; Zhu C; Ruan Y; Fan L; Ruan Z; Chen Q; Yuan J; Xu Y; Wang H; Wei Q
Biomed Res Int; 2022; 2022():7488708. PubMed ID: 35342753
[TBL] [Abstract][Full Text] [Related]
34. Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer.
Kondrotienė A; Daukša A; Pamedytytė D; Kazokaitė M; Žvirblienė A; Daukšienė D; Simanavičienė V; Klimaitė R; Golubickaitė I; Stakaitis R; Šarauskas V; Verkauskienė R; Žilaitienė B
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899424
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
[TBL] [Abstract][Full Text] [Related]
36. Identifying gene modules of thyroid cancer associated with pathological stage by weighted gene co-expression network analysis.
Tang X; Huang X; Wang D; Yan R; Lu F; Cheng C; Li Y; Xu J
Gene; 2019 Jul; 704():142-148. PubMed ID: 30965127
[TBL] [Abstract][Full Text] [Related]
37. Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis.
Oskouie AA; Ahmadi MS; Taherkhani A
Microrna; 2022; 11(1):73-87. PubMed ID: 35068400
[TBL] [Abstract][Full Text] [Related]
38. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.
Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY
Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061
[TBL] [Abstract][Full Text] [Related]
39. microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor.
Xu CB; Liu XS; Li JQ; Zhao X; Xin D; Yu D
J Cell Biochem; 2019 Jun; 120(6):10830-10846. PubMed ID: 30706537
[TBL] [Abstract][Full Text] [Related]
40. A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients.
Dong J; Xu M
Oncol Rep; 2019 Jun; 41(6):3233-3243. PubMed ID: 31002358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
